Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 9, 2026World Journal of CardiologyOpen Access

Reimagining risk stratification: Dipeptidyl peptidase 3 in the new era of cardiovascular biomarkers

View Full Paper
Ask AI
Bookmark
Share

Key result

Dipeptidyl peptidase 3 (DPP3) is a highly specific biomarker for cardiogenic shock, offering prognostic value and potential as a therapeutic target.

Authors

DRDavide RamoniEnte Ospedaliero CantonaleLLLuca LiberaleGeneral CardiologyFCFederico Carbone

Discussion

Loading...

Member takes

Implication

This editorial discusses the clinical utility of dipeptidyl peptidase 3 in cardiovascular biomarkers, suggesting improved patient outcomes through enhanced prediction algorithms.

Key Points

  • To explore the potential of dipeptidyl peptidase 3 as a novel cardiovascular biomarker for risk stratification and therapeutic decision-making.
  • Analyzed the role of dipeptidyl peptidase 3 in cardiovascular research.
  • Evaluated its specificity and prognostic value in cardiogenic shock.
  • Discussed integration into multi-marker panels and predictive algorithms.
  • Dipeptidyl peptidase 3 is highly specific for cardiogenic shock.
  • Circulating levels of DPP3 are linked to myocardial depression and blood pressure regulation.
  • Incorporating DPP3 into predictive models improves patient stratification.

Cite This Study

Ramoni et al. (2025) studied this question. Dipeptidyl peptidase 3 (DPP3) is a highly specific biomarker for cardiogenic shock, offering prognostic value and potential as a therapeutic target.

synapsesocial.com/papers/696128f644c2cd6c68456c93https://doi.org/10.4330/wjc.v17.i12.113443
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Novel cardiac biomarkers and multiple-marker approach in the early detection, prognosis, and risk stratification of cardiac diseases2025 · 12 citations